Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Peripheral blood non-canonical small non-coding RNAs as novel biomarkers in lung cancer and pulmonary tuberculosis (validation cohort)

ABSTRACT: Peripheral blood non-canonical small non-coding RNAs as novel biomarkers in lung cancer and pulmonary tuberculosis (validation cohort)

PROVIDER: PRJNA625982 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR11563522.fastq.gz	Fastqsanger.gz
	SRR11563523.fastq.gz	Fastqsanger.gz
	SRR11563524.fastq.gz	Fastqsanger.gz
	SRR11563525.fastq.gz	Fastqsanger.gz
	SRR11563526.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 35

Similar Datasets

Peripheral blood non-canonical small non-coding RNAs as novel biomarkers in lung cancer and pulmonary tuberculosis (discovery cohort)

Project description:Peripheral blood non-canonical small non-coding RNAs as novel biomarkers in lung cancer and pulmonary tuberculosis (discovery cohort)

| PRJNA625983 | ENA

Tuberculosis biomarker validation cohort

Project description:Tuberculosis biomarker validation cohort

| PRJNA616117 | ENA

Peripheral blood non-canonical small non-coding RNAs as novel biomarkers in lung cancer and pulmonary tuberculosis (validation cohort)

Project description:One unmet challenge in current lung cancer diagnosis is to accurately differentiate lung cancer patients from those with other lung diseases with similar clinical symptoms and radiological features. Previous studies have reported cases of misdiagnosis for patients with lung cancer mimicking pulmonary tuberculosis (TB) or for TB patients with multiple lung nodules mimicking lung cancer progression, which is concerning for clinical practice in TB-endemic countries/regions. Here, we develop a molecular signature composed of non-canonical small non-coding RNAs in human peripheral blood mononuclear cells (PBMCs), including tRNA-derived small RNAs (tsRNAs), rRNA-derived small RNAs (rsRNAs), and YRNA-derived small RNAs (ysRNAs). This signature consists of i) the tsRNAs derived from tRNA-Ala, tRNA-Asn, tRNA-Leu, tRNA-Lys, and tRNA-Tyr that are upregulated in the lung cancer patients relative to the healthy controls and patients with pulmonary TB, ii) the rsRNAs derived from rRNA-5S that are upregulated in the lung cancer patients but downregulated in TB patients relative to the controls, and iii) the ysRNAs originating from YRNA-RNY1 that are downregulated in the lung cancer patients but upregulated in the TB patients compared with the controls. This diagnostic signature discriminates between healthy controls, lung cancer patients, and pulmonary TB subjects with high accuracy in both the discovery and validation cohorts. We conclude that the PBMC tsRNAs, rsRNAs, and ysRNAs are informative for both screening for and discriminating between lung cancer and pulmonary TB.

2020-11-16 | GSE148862 | GEO

Urine miRNA transcriptome of prostate cancer patients [Validation cohort]

Project description:Intra-individual stability of the urine miRNA transcriptome was examined by investigating longitudinal changes over time in a cohort of patients with localized prostate cancer. Using training and validation cohorts, urinary miRNA biomarkers are characterized and validated their utility to identify aggressive prostate cancer.

2019-10-24 | GSE104430 | GEO

Systems Biology to Identify Biomarkers of Neonatal Vaccine Immunogenicity - Papua New Guinea (PNG) Validation cohort [methylation]

Project description:Systems Biology to Identify Biomarkers of Neonatal Vaccine Immunogenicity - Papua New Guinea (PNG) Validation cohort [methylation]

| PRJNA1129141 | ENA

Peripheral blood non-canonical small non-coding RNAs as novel biomarkers in lung cancer and pulmonary tuberculosis (discovery cohort)

2020-11-16 | GSE148861 | GEO

High-frequency recurrence index for predicting multiple recurrences in non-muscle-invasive bladder cancer (Validation cohort)

Project description:Non-muscle invasive bladder cancer (NMIBC) has a recurrence rate of more than 50% after transurethral resection (TUR) and Calmette-Guérin (BCG) treatment. This study aimed to develop a high-frequency recurrence index (HfRI) to predict multiple recurrences in NMIBC patients and guide personalized treatment strategies. In this study, we analyzed transcriptome data (Discovery cohort) of 45 high-risk NMIBC patients who received intravesical BCG treatment, including patients with >=2 recurrences, to identify genes significantly associated with high-frequency recurrence and construct a signature. In addition, we validated the predictive performance using transcriptome data of 94 patients (Validation cohort).

2026-02-07 | GSE294705 | GEO

Large-scale Proteomics Profiling of Peripheral Blood of DM1 patients identifies biomarkers for disease severity and physical activity - Validation cohort

Project description:Myotonic Dystrophy type 1 (DM1) is a progressive multisystem disease with large heterogeneity in disease onset, symptom development, progression rates and severity. This poses significant challenges to the design of clinical trials. To overcome some of these challenges, this study aims to identify protein biomarkers in serum that can serve as measures of therapy response. Biomarker discovery was performed in serum samples of DM1 patients in the OPTIMISTIC trial, which is deposited elsewhere. The dataset in this project comprises data generated on the Canadian cohort of DM1 patients which was used as external validation cohort.

2026-01-19 | PXD060035 | Pride

Discovery and validation of urinary molecular signature of early sepsis (validation cohort)

Project description:Discovery and validation of urinary molecular signature of early sepsis (validation cohort)

| PRJNA439295 | ENA

Genomic biomarkers from urine cells indicate a unique metabolomic difference between sepsis and sterile inflammation (validation cohort)

Project description:Genomic biomarkers from urine cells indicate a unique metabolomic difference between sepsis and sterile inflammation (validation cohort)

| PRJNA707444 | ENA

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data